How Does NGM Biopharmaceuticals Inc (NGM) Stock Rank on Wall Street Thursday?

Thursday, April 28, 2022 03:29 PM | InvestorsObserver Analysts

Mentioned in this article

Wall Street is positive on NGM Biopharmaceuticals Inc (NGM). On average, analysts give NGM Biopharmaceuticals Inc a Strong Buy rating. The average price target is $35.2, which means analysts expect the stock to add by 164.86% over the next twelve months. That average ranking earns NGM Biopharmaceuticals Inc an Analyst Rating of 72, which is better than 72% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating NGM a Strong Buy today. Find out what this means to you and get the rest of the rankings on NGM!
See Full NGM Report

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With NGM Biopharmaceuticals Inc Stock Today?

NGM Biopharmaceuticals Inc (NGM) stock is down -8.66% while the S&P 500 is higher by 2.79% as of 3:26 PM on Thursday, Apr 28. NGM has fallen -$1.26 from the previous closing price of $14.55 on volume of 407,694 shares. Over the past year the S&P 500 has risen 2.81% while NGM has fallen -53.58%. NGM lost -$1.56 per share the over the last 12 months. Click Here to get the full Stock Report for NGM Biopharmaceuticals Inc stock.

Share this article:

Related Articles